Danone acquires Functional Formularies
Press release – Paris, May 01, 2024
Danone acquires Functional
Formularies
Danone announces today it has successfully
completed the acquisition of Functional Formularies, a leading
whole foods tube feeding business in the US, from Swander Pace
Capital.
As part of the Renew Danone strategy, this
acquisition strengthens Danone’s Medical Nutrition portfolio in the
US by further expanding its enteral tube feeding ranges.
Juergen Esser, Deputy CEO and CFO,
said:
“As a global leader in Medical Nutrition, we are
delighted to welcome Functional Formularies to Danone. We are
confident that with the addition of the greatly differentiated
product portfolio of Functional Formularies, which complements our
existing Real Food Blends branded range, we are even better
positioned to support the nutritional needs of tube-fed families
and patients.”
About Functional
Formularies
Functional Formularies is a leading provider of
organic, whole food, shelf-stable feeding tube formulas. The
Company offers unique, organic, and whole food alternatives to
traditional feeding tube formulas. Liquid Hope® and Nourish® are
nutritionally complete, plant-based, and USDA-certified organic.
The Company offers its products to institutional customers in
hospital and long-term care settings and to retail customers online
throughout the U.S. and Canada. To learn more about Functional
Formularies products, visit www.functionalformularies.com.
About Danone
(www.danone.com)
Danone is a leading global food and beverage
company operating in three health-focused, fast-growing and
on-trend Categories: Essential Dairy & Plant-Based products,
Waters and Specialized Nutrition. With a long-standing mission of
bringing health through food to as many people as possible, Danone
aims to inspire healthier and more sustainable eating and drinking
practices while committing to achieve measurable nutritional,
social, societal and environment impact. Danone has defined its
“Renew” strategy to restore growth, competitiveness, and value
creation for the long-term. With almost 90,000 employees, and
products sold in over 120 markets, Danone generated €27.6 billion
in sales in 2023. Danone’s portfolio includes leading international
brands (Actimel, Activia, Alpro, Aptamil, Danette, Danio, Danonino,
evian, Nutricia, Nutrilon, Volvic, among others) as well as strong
local and regional brands (including AQUA, Blédina, Bonafont, Cow
& Gate, Mizone, Oikos and Silk). Listed on Euronext Paris and
present on the OTCQX platform via an ADR (American Depositary
Receipt) program, Danone is a component stock of leading
sustainability indexes including the ones managed by Moody’s and
Sustainalytics, as well as MSCI ESG Indexes, FTSE4Good Index
Series, Bloomberg Gender Equality Index, and Access to Nutrition
Index. Danone’s ambition is to be B CorpTM certified at global
level in 2025.
o o O o o
FORWARD-LOOKING STATEMENTS
This press release contains certain
forward-looking statements concerning Danone. In some cases, you
can identify these forward-looking statements by forward-looking
words, such as “estimate”, “expect”, “anticipate”, “project”,
“plan”, “intend”, “objective”, “believe”, “forecast”, “guidance”,
“foresee”, “likely”, “may”, “should”, “goal”, “target”, “might”,
“will”, “could”, “predict”, “continue”, “convinced” and
“confident,” the negative or plural of these words and other
comparable terminology. Forward looking statements in this document
include, but are not limited to, predictions of future activities,
operations, direction, performance and results of Danone.
Although Danone believes its expectations are
based on reasonable assumptions, these forward-looking statements
are subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated in these
forward-looking statements. For a detailed description of these
risks and uncertainties, please refer to the “Risk Factor” section
of Danone’s Universal Registration Document (the current version of
which is available at www.danone.com).
Subject to regulatory requirements, Danone does
not undertake to publicly update or revise any of these
forward-looking statements. This document does not constitute an
offer to sell, or a solicitation of an offer to buy Danone
securities.
Danone (BIT:DNN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Danone (BIT:DNN)
Gráfica de Acción Histórica
De May 2023 a May 2024
